This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $95.18, moving +1.58% from the previous trading session.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $130.17 in the latest trading session, marking a -0.39% move from the prior day.
Company News for Jan 3, 2022
by Zacks Equity Research
Companies In The News Are: PFE, CTRA, AMD, XLNX, NVAX.
Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine
by Zacks Equity Research
Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group
by Zacks Equity Research
Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.
Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More
by Zacks Equity Research
Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.
Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India
by Zacks Equity Research
Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.
Santa Rally Takes a Breather Going into Mid-Week
by Mark Vickery
With only three more trading days before the end of 2021, we're seeing something we haven't for five years: the S&P outperforming the Nasdaq.
Top Stock Picks for Week of December 27, 2021
by Panel Of Zacks Experts
A Biotech Company and an Under-The-Radar Cloud Transformation Stock to Round Out the Year
Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.
Markets Stay Up on Omicron News; Home Sales in Focus
by Mark Vickery
Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.
Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.
Novavax (NVAX) Commences COVID-19 Vaccine Booster Study
by Zacks Equity Research
Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.
Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO
by Zacks Equity Research
Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
Emergent (EBS) Begins Dosing in Study on Influenza Vaccine
by Zacks Equity Research
Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.
Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors
by Zacks Equity Research
Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab
by Zacks Equity Research
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns
by Zacks Equity Research
Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax